Probiotic Research in Therapeutics

Volume 5: Metabolic Diseases and Gut Bacteria

Kanwaljit Chopra, Mahendra Bishnoi, Kanthi Kiran Kondepudi (Herausgeber)

Buch | Hardcover

275 Seiten

2022 | 1st ed. 2022
Springer Verlag, Singapore
978-981-16-8443-2 (ISBN)

Artikel merken

This volume focuses on the potential use of probiotics in treating metabolic disorders such as diabetes mellitus, metabolic acidosis, and gut dysbiosis. Chapters draw an association between gut microbiota and its diversity with metabolic diseases like diabetes, obesity, related liver and gut disorders; gut-brain axis; increased inflammation, and a compromised immune system resulting from these manifestations and scope of intervention with probiotics. Special attention is laid on describing the mechanisms of action of such beneficial effects of probiotic administration. The ability of probiotics to decrease metabolic endotoxemia by restoring the disrupted intestinal mucosal barrier is also included.
The volume is a comprehensive compilation describing the scope and application of probiotic and prebiotic therapy in treating metabolic disorders. Readers will discover how probiotics are not just confined to the microbiology industry but are showing promising results in the medical and pharmaceutical sectors.

Dr. Indu Pal Kaur is presently working as the Professor and Chairperson at the University Institute of Pharmaceutical Sciences (UIPS). She has more than 25 years of teaching and research experience. Her research forte enhances the performance of small and large biomolecules, including probiotics using active-tailored delivery systems. The emphasis of her work lies in Industrial and clinical translation. She has delivered 50 Invited Talks; published > 145 high impact International publications and 21 book chapters; edited four books and 4 Journal special issues; and > 150 presentations have been made by her research group, with 30 sentenced as best presentations. Prof. Kanwaljit Chopra, the former Chairperson of the University Institute of Pharmaceutical Sciences, has prolific experience of 28 years in research and holds distinguished expertise in Neuropharmacology, Diabetes & Metabolic Diseases, Pain, Inflammation, and Menopausal complications. Shehas more than 215 international and national publications in high-impact journals, acclaimed globally for her research work. She has received eleven prestigious national and international awards. She has fetched grants of over 1.5 Crores from the Government as well as Industry. She has been an active member of National and International societies. Her “Reverse Pharmacology” approach has provided strong leads to the scientific community for the translational potential of various moieties of natural origin. Dr. Mahendra Bishnoi is working as Scientist E, Food and Nutritional Biotechnology, National Agri-Food Biotechnology Institute, Mohali. He is presently leading a group of young researchers dedicated to metabolic disorders (obesity and type-2 diabetes) research with a particular focus on nutrition and diet, the development of molecular evidence-based functional foods, and nutraceuticals. His scientific work is well recognized in more than 120 peer-reviewed and high-impactfactor scientific journals, with around 4000 citations. Dr. Bishnoi is an Alexander von Humboldt Experienced Fellow, Early and Mid-Career Research (EMCR) fellow of Indian National Science Academy (INSA), Melvin Yahr awardee from World Federation of Neurosciences. Dr. Kondepudi is presently working as Scientist-E in the Food & Nutrition Biotechnology Division at National Agri-Food Biotechnology Institute, an autonomous institute under the Department of Biotechnology, Government of India. Dr. Kondepudi is actively working on developing dietary interventions that could beneficially modulate the gut bacteria and could protect from proinflammatory stress underlying many diseases with an overall goal to develop functional foods based on millets and their bioactive ingredients, dietary fibers, prebiotics, probiotics, and other functional ingredients from different plant sources. His group uses rodent models, nutrigenomic and metagenomic approaches for evaluating the efficacy of bioactive ingredients and functional foods.

Chapter 1: Gut-Brain Axis: Role in Hunger and Satiety.- Chapter 2: Antiobesity Activities of Probiotics and Dairy based Ingredients.- Chapter 3: Effect of Pre/Probiotic Supplementation on Metabolic Endotoxemia.- Chapter 4: Probiotics in the management of Diabetes.- Chapter 5: Intestinal microbiota modulation for type 1 and type 2 diabetes prevention.- Chapter 6: Mechanisms of beneficial effects of probiotics in diabetes mellitus.- Chapter 7: Preventive and therapeutic role of Probiotics in type- 2 diabetes and its associated complications.- Chapter 8: Protective effect of probiotic in alcohol induced liver disorders.- Chapter 9: Molecular Mechanism of Beneficial Effects of Probiotics in Alcohol-Induced Liver Disorder.- Chapter 10: Effect of probiotic supplementation on modulation of serum lipids.- Chapter 11: Use of prebiotics for addressing gut dysbiosis and achieving healthy gut- brain axis.- Chapter 12: Designer Probiotics in Metabolic Disorders.- Chapter 13: Animal models used forstudying the benefits of probiotics in metabolic disorders.

Erscheinungsdatum	09.05.2022
Mitarbeit	Chef-Herausgeber: Indu Pal Kaur
Zusatzinfo	1 Illustrations, black and white; XIV, 275 p. 1 illus.
Verlagsort	Singapore
Sprache	englisch
Maße	155 x 235 mm
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
	Medizin / Pharmazie ► Pharmazie
	Studium ► Querschnittsbereiche ► Infektiologie / Immunologie
	Naturwissenschaften ► Chemie ► Technische Chemie
	Technik
Schlagworte	Designer probiotics • Gut dysbiosis • Metabolic acidosis • Metabolic Endotoxemia • Micrbiome • Regulatory requirements • safety concerns
ISBN-10	981-16-8443-X / 981168443X
ISBN-13	978-981-16-8443-2 / 9789811684432
Zustand	Neuware